A Practical Model Evaluating Antiviral Cytokines by Natural Killer Cells in Treatment Naïve Patients with Chronic Hepatitis B Virus Infection

Abstract Natural killer (NK) cells play a major role in anti-viral immunity as first line defense during hepatitis B infection, particularly in untreated patients whose T cells functions are profoundly impaired. Cytokine interferon (IFN)-γ and tumor necrosis factor (TNF)-α produced by NK cells are i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiaoyan Li, Yurong Gu, Xiaobo Guo, Lin Gu, Liang Zhou, Xiaojuan Wu, Xueqin Wang, Zania Stamataki, Yuehua Huang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/1cde706b7a2545e5b6139658b577ee7a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1cde706b7a2545e5b6139658b577ee7a
record_format	dspace
spelling	oai:doaj.org-article:1cde706b7a2545e5b6139658b577ee7a2021-12-02T11:51:13ZA Practical Model Evaluating Antiviral Cytokines by Natural Killer Cells in Treatment Naïve Patients with Chronic Hepatitis B Virus Infection10.1038/s41598-017-06192-12045-2322https://doaj.org/article/1cde706b7a2545e5b6139658b577ee7a2017-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-06192-1https://doaj.org/toc/2045-2322Abstract Natural killer (NK) cells play a major role in anti-viral immunity as first line defense during hepatitis B infection, particularly in untreated patients whose T cells functions are profoundly impaired. Cytokine interferon (IFN)-γ and tumor necrosis factor (TNF)-α produced by NK cells are important anti-viral factors. However, there is lack of a quantifiable model to evaluate cytokine responses by NK cells. In this study, almost half of the patients (47.9%) beyond treatment criteria had high cytokine activity, although it was lower than those recommended for antiviral therapy (78.2%). Moreover, we developed a model that low levels of HBsAg, HBcAb, and albumin and high fibrosis values predicted strong antiviral cytokine production by NK cells. Based on the cut-off score (0.361) obtained from the multivariable model, patients with 67%, 8%, 92%, and 74% in immune-active (IA), immune-tolerant (IT), immune-inactive (IC), and grey zone (GZ), respectively, showed active antiviral cytokines produced by NK cells. These results suggest that those who possess activated cytokine responses beyond the current treatment criteria may have potential implications for the timing of antiviral therapy to achieve better virus control.Xiaoyan LiYurong GuXiaobo GuoLin GuLiang ZhouXiaojuan WuXueqin WangZania StamatakiYuehua HuangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Xiaoyan Li Yurong Gu Xiaobo Guo Lin Gu Liang Zhou Xiaojuan Wu Xueqin Wang Zania Stamataki Yuehua Huang A Practical Model Evaluating Antiviral Cytokines by Natural Killer Cells in Treatment Naïve Patients with Chronic Hepatitis B Virus Infection
description	Abstract Natural killer (NK) cells play a major role in anti-viral immunity as first line defense during hepatitis B infection, particularly in untreated patients whose T cells functions are profoundly impaired. Cytokine interferon (IFN)-γ and tumor necrosis factor (TNF)-α produced by NK cells are important anti-viral factors. However, there is lack of a quantifiable model to evaluate cytokine responses by NK cells. In this study, almost half of the patients (47.9%) beyond treatment criteria had high cytokine activity, although it was lower than those recommended for antiviral therapy (78.2%). Moreover, we developed a model that low levels of HBsAg, HBcAb, and albumin and high fibrosis values predicted strong antiviral cytokine production by NK cells. Based on the cut-off score (0.361) obtained from the multivariable model, patients with 67%, 8%, 92%, and 74% in immune-active (IA), immune-tolerant (IT), immune-inactive (IC), and grey zone (GZ), respectively, showed active antiviral cytokines produced by NK cells. These results suggest that those who possess activated cytokine responses beyond the current treatment criteria may have potential implications for the timing of antiviral therapy to achieve better virus control.
format	article
author	Xiaoyan Li Yurong Gu Xiaobo Guo Lin Gu Liang Zhou Xiaojuan Wu Xueqin Wang Zania Stamataki Yuehua Huang
author_facet	Xiaoyan Li Yurong Gu Xiaobo Guo Lin Gu Liang Zhou Xiaojuan Wu Xueqin Wang Zania Stamataki Yuehua Huang
author_sort	Xiaoyan Li
title	A Practical Model Evaluating Antiviral Cytokines by Natural Killer Cells in Treatment Naïve Patients with Chronic Hepatitis B Virus Infection
title_short	A Practical Model Evaluating Antiviral Cytokines by Natural Killer Cells in Treatment Naïve Patients with Chronic Hepatitis B Virus Infection
title_full	A Practical Model Evaluating Antiviral Cytokines by Natural Killer Cells in Treatment Naïve Patients with Chronic Hepatitis B Virus Infection
title_fullStr	A Practical Model Evaluating Antiviral Cytokines by Natural Killer Cells in Treatment Naïve Patients with Chronic Hepatitis B Virus Infection
title_full_unstemmed	A Practical Model Evaluating Antiviral Cytokines by Natural Killer Cells in Treatment Naïve Patients with Chronic Hepatitis B Virus Infection
title_sort	practical model evaluating antiviral cytokines by natural killer cells in treatment naïve patients with chronic hepatitis b virus infection
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/1cde706b7a2545e5b6139658b577ee7a
work_keys_str_mv	AT xiaoyanli apracticalmodelevaluatingantiviralcytokinesbynaturalkillercellsintreatmentnaivepatientswithchronichepatitisbvirusinfection AT yuronggu apracticalmodelevaluatingantiviralcytokinesbynaturalkillercellsintreatmentnaivepatientswithchronichepatitisbvirusinfection AT xiaoboguo apracticalmodelevaluatingantiviralcytokinesbynaturalkillercellsintreatmentnaivepatientswithchronichepatitisbvirusinfection AT lingu apracticalmodelevaluatingantiviralcytokinesbynaturalkillercellsintreatmentnaivepatientswithchronichepatitisbvirusinfection AT liangzhou apracticalmodelevaluatingantiviralcytokinesbynaturalkillercellsintreatmentnaivepatientswithchronichepatitisbvirusinfection AT xiaojuanwu apracticalmodelevaluatingantiviralcytokinesbynaturalkillercellsintreatmentnaivepatientswithchronichepatitisbvirusinfection AT xueqinwang apracticalmodelevaluatingantiviralcytokinesbynaturalkillercellsintreatmentnaivepatientswithchronichepatitisbvirusinfection AT zaniastamataki apracticalmodelevaluatingantiviralcytokinesbynaturalkillercellsintreatmentnaivepatientswithchronichepatitisbvirusinfection AT yuehuahuang apracticalmodelevaluatingantiviralcytokinesbynaturalkillercellsintreatmentnaivepatientswithchronichepatitisbvirusinfection AT xiaoyanli practicalmodelevaluatingantiviralcytokinesbynaturalkillercellsintreatmentnaivepatientswithchronichepatitisbvirusinfection AT yuronggu practicalmodelevaluatingantiviralcytokinesbynaturalkillercellsintreatmentnaivepatientswithchronichepatitisbvirusinfection AT xiaoboguo practicalmodelevaluatingantiviralcytokinesbynaturalkillercellsintreatmentnaivepatientswithchronichepatitisbvirusinfection AT lingu practicalmodelevaluatingantiviralcytokinesbynaturalkillercellsintreatmentnaivepatientswithchronichepatitisbvirusinfection AT liangzhou practicalmodelevaluatingantiviralcytokinesbynaturalkillercellsintreatmentnaivepatientswithchronichepatitisbvirusinfection AT xiaojuanwu practicalmodelevaluatingantiviralcytokinesbynaturalkillercellsintreatmentnaivepatientswithchronichepatitisbvirusinfection AT xueqinwang practicalmodelevaluatingantiviralcytokinesbynaturalkillercellsintreatmentnaivepatientswithchronichepatitisbvirusinfection AT zaniastamataki practicalmodelevaluatingantiviralcytokinesbynaturalkillercellsintreatmentnaivepatientswithchronichepatitisbvirusinfection AT yuehuahuang practicalmodelevaluatingantiviralcytokinesbynaturalkillercellsintreatmentnaivepatientswithchronichepatitisbvirusinfection
_version_	1718395150791606272

A Practical Model Evaluating Antiviral Cytokines by Natural Killer Cells in Treatment Naïve Patients with Chronic Hepatitis B Virus Infection

Ejemplares similares